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Abstract: Exosome-like extracellular vesicles (ELVs) contain biomolecules that have potential as
diagnostic biomarkers, such as proteins, micro-RNAs (miRNAs), and lipids. However, it is difficult
to enrich ELVs consistently with high yield and purity from clinical samples, which hampers the
development of ELV biomarkers. This is particularly true for miRNAs in protein-rich plasma. Hence,
we modified ELV isolation protocols of three commercially available polymer-precipitation-based kits
using proteinase K (PK) treatment to quantify ELV-associated miRNAs in human plasma. We compared
the yield, purity, and characteristics of enriched plasma ELVs, and measured the relative quantity of
three selected miRNAs (miR-30c, miR-126, and miR-192) in ELVs using six human plasma samples.
Compared with the original protocols, we demonstrated that ELVs can be isolated with PK treatment
with high purity (i.e., lack of non-exosomal proteins and homogeneous size of vesicles) and yield
(i.e., abundancy of exosomal markers), which were dependent on kits. Using the kit with the highest
purity and yield with PK treatment, we successfully quantified ELV miRNAs (levels of 45%–65% in
total plasma) with acceptable variability. Collectively, ELV enrichment using the modified easy-to-use
method appears suitable for the analysis of miRNAs, although its clinical applicability needs to be
confirmed in larger clinical studies.
Keywords: extracellular vesicle; plasma miRNA; biomarker; polymer-precipitation; proteinase K
1. Introduction
Exosomes are extracellular vesicles (EVs) with a diameter of approximately 30–150 nm and a
density of 1.13~1.19 g/mL that are secreted from most cells through sorting pathways. Interest in the
biologic functions of exosomes and the molecular contents of exosomes, including nucleic acids, proteins,
and lipids, is growing exponentially. EVs are found in biologic fluids such as blood, plasma, urine,
saliva, milk, and cerebrospinal fluid, and their biologic contents can be used as diagnostic biomarkers
or therapeutic targets [1]. Although various methods, including differential ultracentrifugation (UC),
density-gradient ultracentrifugation (DG-UC), size-exclusion chromatography (SEC), and polymer-based
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precipitation (PP), allow exosome-like extracellular vesicles (ELVs) to be isolated from biologic fluids or
cell culture media, several issues remain unresolved, especially in terms of clinical applications, including
the aggregation of vesicles, low recovery, necessity of a large sample volume, and contamination with
soluble proteins and lipoproteins [2,3]. In particular, co-isolation with ELV-sized lipoproteins or protein
precipitates can interfere with the analysis of ELV-associated micro-RNAs (miRNAs), because certain
lipoproteins (e.g., high-density lipoprotein (HDL)) may carry miRNAs [4].
miRNAs are small non-coding RNAs, approximately 22 nucleotides long, that regulate various
biologic processes by binding to the complementary sites of the 3′-untranslated regions of target
messenger RNAs (mRNAs) and silencing them translationally or by mRNA degradation [5]. Circulating
miRNAs are protected from ribonucleases by binding to RNA-binding proteins [6–8] or by selective
encapsulation by ELVs [9], which increases the stability of miRNAs in biofluids. Considering the
sorting of miRNAs into ELVs, several mechanisms of selective miRNA loading into exosomes have
been postulated [10,11], and it has been increasingly recognized that the quantity of specific miRNAs
or miRNA profiles in ELVs are altered in certain disease states [12–17]. Therefore, ELV-associated
miRNAs might be potential biomarkers for disease diagnosis; they could also be used to monitor
disease progression [18–20] or as therapeutic targets [21].
Various methods to isolate ELVs and to profile ELV-associated miRNAs in body fluids for disease
diagnosis are available, including UC, DG-UC, SEC, and PP [22]. The method most commonly used is
ELV isolation by differential UC, which is relatively simple and cheap [23]. However, this technique
is time-consuming and results in a low recovery rate. It requires an ultracentrifuge, and ELVs may
get mechanically damaged. Additionally, misinterpretation of biomarker levels may occur because
of co-sediments such as non-specific particles (e.g., protein aggregates) or the non-specific binding
of molecules to the surface of exosomes [24,25]. If necessary, DG-UC can be applied, which yields
the purest fraction of exosomes with fewer contaminations when compared with UC. However,
DG-UC is time-consuming and difficult to use. The ELV yield is low, and there is an apparent lack of
reproducibility between laboratories, which limits its clinical use [26]. SEC separates intact vesicles
depending on particle size using an SEC column. This method is relatively simple and can purify
exosomes of regular shape. However, it is possible that other vesicles with similar sizes or lipoproteins
are co-isolated [27], and the exosome yield is low [22].
PP is one of the most commonly used exosome enrichment methods. Commercially available kits
are easy, fast, and simple; provide a high-throughput method for small sample volumes; and are the
most reliable method used for clinical applications. However, previous studies have argued that PP
provides low purity because of the co-precipitation of contaminants such as protein aggregates [22,26].
Therefore, the results obtained from exosomes co-isolated via a commercialized PP kit might be
questionable. In particular, miRNA can be transported in plasma in non-vesicular form by binding
to HDL [7,28] and argonaute proteins [6,29]. Non-vesicular and vesicular miRNAs need to be
discriminated to develop ELV miRNA biomarkers.
In the present study, we modified the ELV isolation methods provided by the manufacturers
of PP kits by adding protease K (PK) and acidification to maximize the advantages of PP-based
ELV isolation and minimize contamination with non-vesicular miRNA. We evaluated ELV purity by
detecting representative exosomal markers and non-exosomal proteins, morphological assessment
by transmission electron microscopy (TEM), and the size distribution of the vesicles. In addition,
we tested the effects of acidification of the samples on ELV protein quantities and the expression of
exosomal markers. Furthermore, we quantified specific miRNAs using quantitative polymerase chain
reaction (qPCR) in ELVs isolated from human plasma.
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2. Materials and Methods
2.1. Blood Collection and Plasma Preparation
Because anticoagulants are a pre-analytical variable for the ELV yield [30] or subsequent qPCR [31],
we selected ethylenediaminetetraacetic acid (EDTA), the most commonly used anticoagulant, to prepare
the plasma. Fasting blood was drawn from the antecubital vein into EDTA tubes (BD Vacutainer
K2E-EDTA; Beckton and Dickinson, Franklin Lake, NJ) from young healthy volunteers and immediately
centrifuged at 3000× g for 10 min at room temperature (RT). The plasma was transferred to a new
polypropylene tube and centrifuged again at 10,000× g for 20 min at RT to remove platelets, cell debris,
and large particles. The supernatant was transferred to a new tube without disturbing the pellets,
aliquoted, and then stored at −70 ◦C until use. For miRNA analysis in ELVs isolated from plasma, six
elderly subjects (three cognitively normal elderly subjects and three patients with mild Alzheimer’s
disease (AD)) agreed to participate in the study and donated blood. The demographic characteristics
and clinical informations of the subjects are summarized in Supplementary Table S1. The Institutional
Review Board and Ethical Committee of Inha University Hospital approved the study (approval No.:
INHAUH2016-06-010-002). Written informed consent to participate was obtained from all volunteers.
2.2. ELV Isolation
We used three commercially available PP-based kits to isolate ELVs: the ExoQuick Exosome Isolation
Kit for Serum and Plasma (SBI, #EXOQ5A-1; System Biosciences, Palo Alto, CA), the Invitrogen™
Total Exosome Isolation Kit (LT, #4484450; Thermo Fisher Scientific, Waltham, MA), and the miRCURY
Exosome Serum/Plasma Kit (QG, #76603; Qiagen, Venlo, Netherlands). The basic procedures of ELV
isolation were carried out according to the manufacturers’ protocols. Briefly, plasma was incubated with
thromboplastin-D (for SBI kit, #100356; Thermo Fisher Scientific) or thrombin (for QG kit, #36402.01;
SERVA, Heidelberg, Germany) for defibrination, followed by a precipitation procedure. For the LT kit,
plasma was diluted with phosphate-buffered saline (PBS) following the manufacturer’s instructions.
To evaluate the effects of proteinase treatment, we added a broad-spectrum serine proteinase, PK
(Ambion, Austin, TX), to the plasma samples (final concentration: 0.5 or 1.0 mg/mL) before the
precipitation. Plasma samples (0.6 mL) were mixed with PK by brief vortexing and incubated at 37 ◦C
for 10 min. Samples with or without PK treatment were mixed with the precipitation buffer provided
by the manufacturers and incubated at 4 ◦C for 30 min or 1 h following the manufacturers’ instructions.
The precipitated pellets obtained by centrifugation (SBI, 1500× g for 30 min; LT and QG, 10,000× g for
5 min) were re-suspended in 200 µL PBS and used for total protein quantification or for Western blot
analysis after dilution with radioimmunoprecipitation assay (RIPA) buffer. We evaluated the effect of
plasma volume (0.6, 1.0, or 1.7 mL) on ELV enrichment by measuring the protein concentrations of
isolated ELVs. Among the three tested kits, ELVs prepared with the QG kit and 0.5 mg/mL PK showed
the optimal purity and yield (see results); hence, to isolate ELVs using acidification, we treated 0.6 mL
plasma with 50 µL 1N HCl (1:12, v/v) after PK treatment, followed by the precipitation procedure.
The workflow is illustrated in Figure 1.
2.3. Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western Blot Analysis
We characterized isolated ELVs in terms of the presence of proteins normally enriched in exosomes,
including Alix, TSG-101, CD-63, or annexin-5, and the absence of GM130, calnexin, or apolipoprotein
A-1 (apo A-1), proteins that are usually absent in exosomes. Quantification of total proteins in
ELV preparations was performed using a bicinchoninic acid protein assay kit (Pierce, Rockford, IL)
using ELVs in PBS, diluted five times (v/v) with RIPA buffer (50 mM Tris-HCl, 1% NP40, 150 mM
NaCl, 1 mM EDTA, and 0.1% SDS). Twenty micrograms of protein in the ELV preparation were
mixed with reducing sample buffer (50 mM Tris-HCl [pH 6.8], 10% glycerol, 2% SDS, 100 mM
dithiothreitol, and 0.01% bromophenol blue) and separated on 10% SDS-PAGE gels. Proteins were
then transferred to nitrocellulose membranes (#66485, Pall Corporation, Port Washington, NY) and
J. Clin. Med. 2019, 8, 1995 4 of 16
incubated with blocking buffer containing 5% non-fat dried milk in 0.1% Tris-buffered saline-Tween 20
at RT for 1 h. We incubated membranes with primary antibodies (1:1000) against exosomal protein
markers; that is, anti-TSG101 (M-19; Santa Cruz Biotechnology, #sc-6037), anti-CD63 (TS63; Abcam,
#ab59479), anti-Annexin V (Abcam; #ab14196), and anti-Alix (3A9; Cell Signaling Technology, #2171),
or non-exosomal proteins; that is, anti-GM130 (Clone 35/GM130; BD Transduction Laboratory, #610822),
anti-calnexin (AF18; Santa Cruz Biotechnology, #sc-23954), and anti-apo A-1 (069-01; Santa Cruz
Biotechnology, #sc-58230), at 4 ◦C overnight. Specific proteins were detected using an Enhanced
Chemiluminescence Detection System (Pierce) or Immobilon Chemiluminescent HRP Substrate (Merck
Millipore, Temecula, CA, USA). For quantitative analysis, we used a Chemidoc Touch Image system
and Quantity One® 4.6 image analysis software (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Figure 1. Schematic overview of experimental procedures with different protocols to isolate plasma
extracellular vesicles (ELVs). EDTA, ethylenediaminetetraacetic acid; RT, room termperature; QG kit,
miRCURY Exosome Serum/Plasma Kit.
2.4. Morphological Characterization of ELVs by Electron Microscopy
ELVs were visualized using TEM as previously described, with slight modifications [32]. Briefly,
ELV suspensions were diluted 1:50 with PBS. Two microliters of the fresh ELV solution were transferred
onto Formvar-carbon-coated EM grids without fixation and allowed to dry at RT. The grids were then
stained with 1% uranyl acetate for 1 min. Imaging was performed at an acceleration voltage of 75 KV
using a charge-coupled device camera (5 × 5 k, Hamamatsu Photonics, Shizuoka, Japan) coupled to a
H-7100 electron microscope (Hitachi High Technology, Tokyo, Japan).
2.5. Size Distribution Analysis of ELVs
Isolated ELVs were analysed using a Nanosight NS300 instrument with NTA3.2.16 software
(Malvern, Worcestershire, UK) and dynamic light scattering (DLS; Zetasizer Nono ZS ZEN3600;
Malvern) to measure the size distribution and number of particles. For the nanoparticle tracking
analysis (NTA) by the Nanosight instrument, aliquots of the ELV suspensions were diluted in PBS
(1:500) to achieve a particle concentration ranging from 106 to 109 particles/mL. Three runs were
recorded for each sample. We compared the size distribution (mode) and number of particles among
preparations. For the DLS, ELVs containing 100 µg of proteins were diluted in PBS (1 mL), and 3 × 10
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measurement runs with standard settings (refractive index = 1.331, viscosity = 0.89, temperature =
25 ◦C) were performed, as previously described [32]. The intensity of the scattered light was measured
at 175◦. We compared the Z-average for size distribution from preparations measured in triplicate.
Following typical DLS procedures, the peak intensity (% mass) can be detected over a wide range of
size (~10,000 nm), which helps determine the purity of ELV preparations.
2.6. Extraction of RNAs and Amplification of Specific miRNAs
To evaluate the feasibility of isolating ELVs for miRNA research, we measured miRNAs in ELVs
using qPCR. We isolated total RNA directly from the ELV pellets or plasma from six elderly persons
using an RNA extraction kit (miRNeasy Serum/Plasma Advanced Kit, #217204; Qiagen) following the
manufacturer’s instructions, with slight modifications. Briefly, 0.5 mL RNase-free water was added to
the ELV pellets, then mixed by brief vortexing, and incubated for 5 min at RT. Plasma samples (0.5 mL)
or lysed ELVs were mixed with RPL buffer (150 µL) for subsequent RNA elution. Samples mixed with
the precipitation buffer (RPP buffer) were centrifuged at 12,000× g for 3 min at RT, and supernatants
were transferred to new microfuge tubes and mixed with the same volume of isopropanol. The mixture
was transferred to a miRNA spin column (RNeasy UCP MInElute column; Qiagen) and centrifuged
at 8000× g for 15 s. After washing, the samples were eluted using 20 µL RNase-free water. cDNA
was synthesized from 2 µL of extracted RNA using the miRCURY LNA RT Kit (Qiagen, #339340)
following the manufacturer’s instructions. After reverse transcription, cDNA templates were diluted
1:40 and amplified with specific miRNAs. As there are no established ELV miRNAs that can be used
as endogenous housekeeping controls, we measured the levels of miRNAs (i.e., miR-30c, miR-126,
and miR-192) that have been reported to be abundant in ELVs [33]. We used primer sets for miR-30c-5p
(#YP00204783), miR-126-3p (#YP00204227), and miR-192-5p (#YP00204099) from Qiagen, and carried
out qPCR using a BioRad Prime PCR machine. The amplifying conditions using the miRCURY
LNA SYBR GREEN PCR Kit (Qiagen, #339345) and primer sequences are summarized in Table 1.
We simultaneously amplified the specific miRNAs extracted from total plasma or ELVs and compared
the relative miRNA quantities using threshold cycle (Ct) values from plasma (pCt) and ELV (vCt).
Table 1. Quantitative PCR condition for amplification of the specific miRNAs.
miRNA Target Sequences Number ofCycles PCR Condition
miR-30c-5p 5′-UGUAAACAUCCUACACUCUCAGC-3′ 40 PCR initial heat activation; 95 ◦C, 2 min.
Denaturation; 95 ◦C, 10 sec.
Combined anneling/extention; 56 ◦C, 1 min.
miR-126-3p 5′-UCGUACCGUGAGUAAUAAUGCG-3′ 40
miR-192-5p 5′-CUGACCUAUGAAUUGACAGCC-3′ 40
2.7. Statistical Analysis
All data are presented as means ± standard errors. ELV protein quantities and expression levels of
exosomal protein markers across the ELV purification methods were compared by the Mann–Whitney
U test using GraphPad Prism software (version 6.0; GraphPad Software, San Diego, CA, USA).
We considered p < 0.05 as significant.
3. Results
3.1. Molecular Characteristics of Isolated ELVs
We compared the expression levels of exosomal marker proteins (i.e., TSG101, CD63, and annexin 5)
and non-exosomal proteins (i.e., GM130, calnexin, and apo A-1) in PK-treated and non-PK-treated
ELV preparations. In ELVs prepared without PK, abundant expression of exosomal markers as well
as non-exosomal markers were detected with all three kits. However, when samples were treated
with PK, the levels of non-exosomal proteins were drastically reduced, although apo A-1 was scantly
detected in ELV samples treated with 0.5 mg/mL of PK. The levels of exosomal marker proteins were
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also decreased by PK treatment, particularly at high concentrations of PK (1.0 mg/mL), except for
annexin 5. With the SBI kit, the levels of exosomal markers per 20 µg ELV protein were higher than
those of other kits when ELVs were prepared without PK. When samples were treated with 0.5 mg/mL
PK, the levels of TSG101 in 20 µg ELV proteins were lower with the SBI than with the other kits,
and the levels of Alix and CD63 were comparable with other kits, while the levels of annexin 5 were
higher than those with the LT or QG preparation kit. The levels of annexin 5 in ELVs prepared with PK
were significantly higher than those without PK. Treatment with high concentrations of PK (1 mg/mL)
further reduced the level of exosomal markers in all kits. Alix was not detected in samples treated
with 1 mg/mL of PK. Among the three tested kits, ELVs prepared with the QG kit and 0.5 mg/mL PK
showed abundant expression of all measured exosomal markers (Figure 2).
Figure 2. Western blot analyses of exosomal and non-exosomal proteins in ELV preparations using three
kits with or without treatment of proteinase K. (A) Comparison of the expression levels of non-exosomal
markers (GM130, calnexin, ApoA-1) in ELVs prepared by three kits. ELVs prepared without proteinase
K showed the abundant expression of contaminated non-exosomal component, which was drastically
decreased by treatment of proteinase K. A representative blot was shown (n = 6). (B) Expression of
exosomal markers (TSG101, CD63, annexin 5, and Alix) in ELVs prepared by three kits with or without
treatment of proteinase K. (C) Quantification of the expression levels of TSG101, CD63, annexin 5,
and Alix in each ELV preparation showed that the levels of TSG101, CD63, and Alix were decreased
by proteinase K treatment in a dose-dependent manner, while the level of annexin 5 was not (n = 6).
* p < 0.05, ** p < 0.01 by Mann–Whitney U test. SBI, ExoQuick Exosome Isolation Kit for Serum and
Plasma; LT, Invitrogen™ Total Exosome Isolation Kit; QG kit, miRCURY Exosome Serum/Plasma Kit.
3.2. Morphological Characterization of ELVs
In addition to the characterization of exosomal and non-exosomal protein expression in ELVs,
we further characterized ELV preparations by morphological analysis using TEM. As shown in Figure 3,
we clearly observed a round-shaped vesicular population with a heterogeneous size ranging from
approximately 30 to 150 nm. When we added PK during preparation, the probable co-precipitates
surrounding the untreated vesicles were mostly cleared. The morphology of ELVs in samples treated
with HCl was not different from that of samples without acidification.
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Figure 3. Electron microscopic image of exosomes following different isolation method. ELVs were
purified using (A) SBI, (B) LT, (C,D) QIAGEN treated with different concentration of proteinase K (0,
0.5, 1mg/mL), and (D) additionally treated with HCl for acidification of samples to approximately pH
4.0. Diluted suspension containing ELVs was placed on formvar-carbon coated grid and negatively
stained with uranyl acetate. Round-shaped vesicles with a heterogeneous size from 30 to 150 nm
diameter were clearly visualized in all preparations. The horizontal bars indicate 100 nm.
3.3. Comparison of Protein Wuantity According to ELV Isolation Methods
To compare the quantity of ELVs in the samples prepared by the different protocols, we measured
the protein concentrations in ELVs prepared with or without PK, or HCl treatment.
As shown in Table 2, the mean protein concentrations in ELVs without PK treatment were
significantly higher than those with treatment for all kits. The mean protein concentrations of ELV
samples prepared using the QG kit with or without PK treatment were the highest, followed by the SBI
and LT kit. The % coefficient of variation (CV) values for the protein concentrations of each preparation
from the SBI, LT, or QG kit were 6.0%~8.9%, 15.9%~48.0%, and 5.1%~7.8%, respectively. In addition,
acidification of samples followed by ELV precipitation using the QG kit and PK treatment increased
the ELV protein concentration with low %CV values (< 3%) compared with the corresponding samples
without acidification.
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Table 2. Comparison of protein concentration and its variability according to the exosome-like
extracellular vesicle (ELV) preparing methods. QG, miRCURY Exosome Serum/Plasma Kit; SBI,
ExoQuick Exosome Isolation Kit for Serum and Plasma; LT, Invitrogen™ Total Exosome Isolation Kit.
Kit SBI (n = 6) LT (n = 6) QG (n = 6) QG (n = 4)
Acidification - - - - - - - - - + +
Proteinase K (mg/mL) 0 0.5 1 0 0.5 1 0 0.5 1 0.5 1
Protein concentration (mean, mg/mL) 9.7 8.8 7.8 5.8 1.8 0.9 16.1 13.0 12.1 21.7 20.3
%CV 8.9 6.0 8.3 15.9 26.5 48.0 5.1 7.4 7.8 2.4 2.6
3.4. Effect of Acidification on the ELV Markers
In a previous study, acid treatment of cell culture media during ELV preparation significantly
increased the abundance of exosomal markers in the preparations [34]. In concordance with this, we also
observed an increase in the abundance of exosomal marker proteins by acidification of PK-treated
samples (Figure 4). Although the expression levels of CD63 in acid-treated samples were comparable
to non-acidified, but PK-treated samples, the levels of other exosomal markers (i.e., Annexin 5, TSG101,
and Alix) were increased by HCl treatment, as compared with those in non-acidified, but PK-treated
samples. In addition, non-exosomal markers were slightly increased by acidification, although GM130
was still not detected.
Figure 4. Effect of acidification on the level of exosomal and non-exosomal proteins in ELV preparation.
(A) Levels of non-exosomal proteins (GM130, calnexin, and ApoA-1) were scanty by treatment of
proteinase K, while the acidification slightly increased the expression of calnexin and ApoA-1, but not
GM130. (B,C) Among the exosomal markers (TSG101, CD63, Alix, and annexin 5), acidification increased
the level of TSG101, Alix, and annexin 5, as compared with non-acidified, but proteinase-treated ELVs
preparation, while the level of CD63 was comparable. Representative bands were shown (n = 6).
* p < 0.05 vs. ELV with proteinase K 0.5 mg/mL without acidification; # <0.05 vs. ELV with proteinase
1.0 mg/mL without acidification, by Mann–Whitney U test.
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3.5. ELV Protein Concentrations According to Plasma Volume
As the QG kit showed the highest protein concentrations with the lowest %CV, and all tested
exosomal marker proteins were detected, we tested the effect of plasma volume on ELV protein
concentrations using the QG kit. For clinical application, the required plasma volume needs to be
optimized. We compared the ELV protein concentrations in PK-treated preparations from 0.6, 1.0,
and 1.7 mL plasma. Regardless of the starting volume, the ELV pellets were resuspended in 200 µL of
PBS. The mean concentrations of ELV protein (n = 4) normalized by volume of plasma (per mL) were
12.6, 10.7, and 8.8 mg/mL, and the %CVs of the protein concentrations were 9.2%, 7.6%, and 7.8% for
0.6, 1.0, and 1.7 mL of plasma, respectively.
3.6. Size Distribution of ELV Preparations
As shown in Figure 5 and Table 3, when ELVs were prepared without PK treatment, we observed
several subpopulations of differently sized vesicles with multiple concentration peaks in the NTA (mean
sizes: 188.8, 171.8, and 172.5 nm for the SBI, LT, and QG kits, respectively). However, the treatment of
samples with 0.5 mg/mL PK slightly reduced the sizes of vesicles with a homogeneous concentration
peak (mean size: 170.8, 126.2, and 125.4 nm for the SBI, LT, and QG kits, respectively). In ELVs prepared
with the higher PK concentration (1 mg/mL), we observed a mean size and number of vesicles similar
to those of ELVs prepared with 0.5 mg/mL PK, except for the QG kit (two modes of the concentration
peaks). A positive effect of the PK treatment on the homogeneity of vesicle seizes was also observed in
the DLS analysis. In all kits, PK treatment reduced the heterogeneity of the size distribution (Figure S1).
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Figure 5. Size distribution and quantification analysis of ELV preparation by nanoparticle tracking
analysis (NTA). The number of particles (×107) per mL and size distribution for each preparation (1:500
dilution) is shown. The calculated size distribution of particles is depicted as a mean (black line) with
standard error (red shaded area).
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Table 3. Size distribution of ELVs analyzed by nanoparticle tracking analysis (NTA) and dynamic light
scattering (DLS) analysis.
Kit
Proteinase K
(mg/mL)
DLS NTA
Z-Average (d.nm) Polydispersity Index (PdI) Size (Mode ± SD, nm)
SBI
0 106.87 0.56 160.0 ± 17.0
0.5 130.10 0.29 151.2 ± 4.9
1 129.97 0.27 158.1 ± 6.0
LT
0 399.23 0.56 149.2 ± 17.5
0.5 95.70 0.22 101.6 ± 1.1
1 95.38 0.19 101.2 ± 7.1
QG
0 76.98 0.54 126.4 ± 5.6
0.5 73.57 0.28 110.5 ± 6.7
1 90.22 0.23 110.8 ± 16.9
3.7. Relative Quantification of miRNAs in Total Plasma or Isolated ELVs
On the basis of our results of ELV preparations with PK treatment (high yield, purity,
and consistency), we tested the feasibility of our method for clinical research using vesicular miRNAs.
Because we treated plasma with PK, it is likely that ectodomains of membranous proteins spanning
across ELV membranes, as well as possibly contaminating proteins, might have been degraded.
Therefore, our method was considered to be more suitable to detect intra-vesicular proteins or nucleic
acids. To test this, we evaluated the relative levels of miRNAs (Ct values) enriched in ELVs (i.e.,
miR-30c, miR-126, and miR-192) using the PK-treated QG kit method with those found in total plasma
measured with qPCR. We measured all tested miRNAs successfully in the ELV preparations from the
plasma of cognitively normal elderly subjects and patients with AD (Figure 6). Compared with the
miRNA quantities in total plasma (Ct values of plasma miRNAs), the mean quantities of miRNAs
in prepared ELVs (Ct values of ELV miRNAs) were low (2(vCt–pCt) × 100 = 45–65%). The within-run
variability of duplicate measures of miRNAs in plasma and ELVs was very low (mean %CVs < 1%).
Interindividual variations of Ct values for total plasma (1.4%–3.4%) and ELV (1.9%–2.6%) miRNA
amplifications were comparable.
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Figure 6. Quantification of selected miRNAs in plasma or ELV using quantitative PCR. (A) Ct vaules of each miRNA extracted from plasma or ELV (n = 6) ranged
from 28 to 34 cycles. Ct values for ELV miRNA amplification were higher than those for miRNA amplification using total plasma. (B) Relative quantities miRNAs
(ELV/Plasma) are shown. Vertical bars and lines indicate mean and standard deviation, respectively.
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4. Discussion
The aim of this study was to develop an optimized method for isolating ELVs with high yield and
purity from human plasma for ELV-associated miRNA research. We evaluated multiple characteristics
of isolated ELVs and found that treatment of plasma with PK improved the purity of ELVs prepared
using commercially available PP-based ELV isolation kits. Furthermore, our method can successfully
quantify selected miRNAs in ELVs, indicating that the modified method may reduce bias and variability
by unintended contamination with non-vesicular proteins and miRNAs.
Circulating extracellular miRNAs have been identified in all biofluids, and there is increasing
evidence that subsets of miRNAs are associated with EVs, including exosomes [35–37]. miRNAs in ELVs
of certain biofluids, particularly plasma or serum, have been suggested as disease biomarkers [18–20,38].
However, to validate miRNA biomarkers, it is essential to isolate ELVs with high yield and purity,
but low variability from biofluids, and to control pre-analytical variables. Recent studies have suggested
that the yield of ELV-associated RNA from 1 mL biofluid is less than 5 ng [39]; hence, ELV isolation
methods with high purity, but low yield (e.g., filtration-based methods or DG-UC) may limit their
clinical application. Plasma is a complex matrix that contains a variety of proteins, lipids, and circulating
nucleic acids. In particular, a variety of proteins can be co-precipitated during ELV isolation using PP
methods, which can interfere with downstream analyses [40]. Circulating miRNAs are protected by
non-vesicular protein complexes, in addition to vesicular packaging [4,41]. Furthermore, during blood
collection and preparation, certain cellular components can be contaminated by microhaemolysis.
Considering the purity of ELVs, we observed that ELVs isolated by commercially available exosome
isolation kits without PK treatment showed an abundance of apo A-1, calnexin, and GM130, which is
in agreement with a previous study [22]. This result indicates that ELVs prepared using commercial PP
kits without additional measures are contaminated with non-vesicular components (i.e., apo A-1, which
indicates contamination with extracellular miRNA-carrying lipoproteins such as HDL; and calnexin
and GM130, which indicate contamination with intracellular organelles); hence, subsequent miRNA
analyses may produce biased results. Fortunately, we found that treatment of plasma with PK before the
precipitation procedure drastically reduced the amount of apo A-1, calnexin, and GM130 contamination
with all tested kits, indicating that our method significantly removed unintended contamination with
non-vesicular proteins. In fact, the polyethylene glycol PP reagent is not specific for precipitating
EVs, but sterically excludes the macromolecular complexes from water molecules, allowing them to
be precipitated easily by low-speed centrifugation [42]. Therefore, the proteolysis of extravesicular
proteins by PK treatment may prevent co-precipitation of proteins.
Considering the yield of ELVs, treatment of plasma with PK significantly reduced the level of
exosomal markers and protein concentrations compared with PK-free preparations. However, the removal
of contaminating non-vesicular proteins by PK treatment may compromise samples by increasing
homogeneity, which causes the reduction of exosomal markers. It can be speculated that the reduced
levels of Alix, TSG101, and CD63 in PK-treated samples may be caused by a possible partial disruption of
the exosomal membrane integrity by cleavage of the ectodomains of vesicular transmembrane proteins.
However, we could not conclude that our method dramatically reduced the recovery of ELVs [43,44].
We clearly observed intact ELVs in the TEM analysis, and even increased expression of another exosomal
marker, annexin 5, in ELVs from PK-treated samples; this was not the case for non-treated samples.
The results of TEM and immunoblot analysis may be contradictory to the hypothesis of partial disruption
of ELVs by PK treatment. In addition, PK treatment improved the homogeneity of vesicles from a broad
range of sizes and multiple subpopulations to a neat preparation of vesicles with a homogenous size
distribution. Therefore, treatment of PK may change the precipitation efficiency of vesicles by kits
according to the molecular or physical characteristics of subpopulation of ELVs [45,46], although our
hypothesis should be further investigated. Interestingly, we observed a higher peak concentration
of ELV-sized vesicles in PK-treated preparations than in untreated samples. The improvement of
resolution by PK treatment in NTA can be explained by the dissociation of aggregated particles or
removal of co-aggregated non-vesicular particles. However, considering the yield of ELVs, the NTA
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results do not exactly agree with the Western blot results, indicating that the effects of PK on ELV stability
and yield need to be investigated further [2]. The acidification of samples with HCl (approximately pH
4.0) using the QG kit, which showed the lowest variability (<8%), but the highest protein concentrations
(1.5–13.4 times that of other kits) of ELV isolates, significantly preserved the expression levels of
exosomal markers. Ban et al. reported that a low pH increased the yield of exosome isolates [34];
however, they did not provide data on possible contamination of non-vesicular protein complexes.
Here, we observed that acidification increased the recovery of ELV markers in PK-treated samples
without significant loss of sample purity, although the acidification showed slightly increased levels of
calnexin and apo A-1 compared with non-acidified samples. Therefore, our ELV isolation method may
be suitable to investigate circulating ELV-associated miRNAs with minimal non-vesicular impurities
in plasma. Furthermore, our ELV isolation method showed acceptable variability (< 10%) when
measuring ELV protein quantities in isolates.
To test the feasibility of ELV miRNA analyses, we measured the expression of selected miRNAs
(i.e., miR-30c, miR-126, and miR-192) that are abundant in ELVs and compared them with the levels of
total circulating miRNAs [33]. We found that these miRNAs were highly expressed in ELVs isolated
from a small plasma volume (0.6 mL) with consistent levels across disease statuses (cognitively
normal elderly persons and AD patients). However, the sample size was very limited. Furthermore,
the quantification of miRNAs in ELVs prepared by our method showed excellent reproducibility,
which may warrant its clinical applicability. The lower quantity of ELV miRNAs compared with the
miRNA quantities in total plasma may indicate that treatment with PK during ELV preparation may
eliminate non-vesicular miRNAs (e.g., HDL-associated miRNAs). The difference of relative quantities
of miRNA in ELVs compared with total plasma may also be explained by the different intrinsic degrees
of encapsulation according to the specific miRNAs. We did not use internal standards for normalization
of miRNA amplification by qPCR because there are no well-accepted control transcripts available
for data normalization. Further studies will thus be needed once these control transcripts have been
developed. Collectively, ELV preparations using a commercially available PP kit combined with PK
treatment may be a reliable method for ELV miRNA research in a clinical setting.
Our study has several limitations. First, we did not measure the effects of PK treatment on
the purity and yield of ELVs or the quantification of miRNAs in a large number of samples with
various clinical characteristics. Given that there is no valid plasma miRNA biomarkers in ELVs for
AD diagnosis, we tested the clinical feasibility of our method using samples from elderly subjects.
The number of clinical samples was very low (i.e., only six plasma samples from elderly healthy or
Alzheimer’s disease subjects), hence our method could not warrant applicability to clinical studies for
various diseases. Therefore, our method should be further validated for consistency. Nevertheless,
our results showed a reduction of possible contamination with non-vesicular proteins and miRNAs by a
simple modification of protocols of widely used commercial kits. Second, the number of tested miRNAs
was limited. In this study, we aimed at testing the feasibility of our method for miRNA research;
therefore, the clinical applicability should be further evaluated in clinical samples with various diseases
and a variety of miRNAs. Third, although we observed non-exosomal markers, GM130 and calnexin
could not be detected by Western blot analysis in our PK-treated ELV preparation; our results do not
warrant the complete elimination of possible impurities from non-vesicular miRNAs, such as apo A-1.
It is plausible that different ELV isolation methods can be applied for different downstream analyses;
therefore, our method may be applicable for miRNA studies for samples with tolerable impurities.
In addition, our method for ELV isolation and miRNA quantification can be further improved by
combining it with other ELV enrichment methods.
5. Conclusions
In summary, we found that treatment of plasma with PK significantly improved the purity of
ELVs isolated using commercially available kits. In addition, acidification of plasma samples followed
by PK treatment increased the levels of ELV markers. Our enrichment method of ELVs from small
J. Clin. Med. 2019, 8, 1995 14 of 16
volumes of human plasma appears to be an easy, consistent, and clinically feasible tool for ELV
miRNA research. Although further studies in larger clinical sample sets with various disease states are
necessary, our method appears suitable for quantifying ELV-associated miRNAs using qPCR.
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